tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Autolus Therapeutics (AUTL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRNResearch Report), Autolus Therapeutics (AUTLResearch Report) and Venus Concept (VEROResearch Report) with bullish sentiments.

BioMarin Pharmaceutical (BMRN)

Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin Pharmaceutical today and set a price target of $155.00. The company’s shares closed last Friday at $84.25.

According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -4.5% and a 33.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Pacira Pharmaceuticals, and Aquestive Therapeutics.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $113.36, which is a 34.6% upside from current levels. In a report issued on January 7, Truist Financial also maintained a Buy rating on the stock with a $135.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Autolus Therapeutics (AUTL)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Friday at $4.65, close to its 52-week low of $4.60.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 11.5% and a 41.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $12.13, which is a 160.9% upside from current levels. In a report issued on January 3, William Blair also maintained a Buy rating on the stock.

Venus Concept (VERO)

BTIG analyst Marie Thibault maintained a Buy rating on Venus Concept today and set a price target of $7.00. The company’s shares closed last Friday at $1.60.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 28.9% and a 39.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Venus Concept with a $5.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed